Active biphasic pulse stimulation---Home Settings
DeviceDuring this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
NCT Number: NCT03811405
This project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
McKnight Brain Institute--Fixel Center for Neurological Diseases, Gainesville, Florida, United States
Deep brain stimulation (DBS) is a neuromodulatory therapy that is effective in a subset of well selected essential tremor (ET) patients. However, as many as 1/5 of patients may initially improve, but then steadily worsen following the operation. The investigators developed a technique to study a variety of alternative stimulation methods without the use of an invasive repeat surgical intervention.
The electrophysiological effects of non-conventional DBS differ from traditional DBS, however the physiological differences in the setting of human tremor remain largely unknown. This study plans to explore gaps in knowledge of neuromodulation and will collect and contribute essential information to the underlying mechanism of action of DBS. The hypothesis of this project centers around active biphasic stimulation providing a wider therapeutic window and a lower adverse event profile as compared to conventional DBS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
Time frame: 4 hours
The study team will use computer simulation and virtual reconstruction of the brain from pre-operative MRI data to calculate the fiber activation threshold for the duration that each subject is on the home settings versus the biphasic settings. The investigators will assess the feasibility of the patterns to address the worsening of ET that may occur in 20% or more of the ET population. No fiber activation threshold data was collected for the DBS OFF state since the system was not active.
Time frame: 4 hours
The investigators will compare the degree of tremor suppression from the home settings versus active biphasic DBS. The degree of tremor will be quantified by the Fahn-Tolosa-Marin Tremor Rating Scale (sum of motor score parts A and B; range 0 - 116). A higher Tremor Rating Scale score is associated with more severe motor symptoms.
The clinical metrics represent the change from DBS OFF to the active arm (either home settings or biphasic VIN) after 4 hours of stimulation
Time frame: 4 hour
Essential tremor motor physiology will be recorded by the Kinesia ONE accelerometer system. The Kinesia ONE system utilizes a wireless, wearable motion sensor and portable transducer to translate movement metrics into a tremor severity score ranging from 0 (no symptoms) to 4 (severe symptoms). In this study, the reported tremor severity score represents motor function captured after 4 hours of active DBS - under either the participants' home settings or the VIN biphasic configuration.
Time frame: 4 hours
Essential tremor's effect on gait will be assessed by the GAITRite system. Patients will walk along a GAITRite floor mat to have the various gait parameters such as step length measured. The GAITRite system translates movement metrics into an objective kinematic score. In this study, the reported kinematic scores represent motor function captured after 4 hours of active DBS - under either the participants' home settings or the VIN biphasic configuration.
Time frame: 4 hours
Essential tremor's effect on gait will be assessed by the GAITRite system. Patients will walk along a GAITRite floor mat to have the various gait parameters such as stride length measured. The GAITRite system translates movement metrics into an objective kinematic score. In this study, the reported kinematic scores represent motor function captured after 4 hours of active DBS - under either the participants' home settings or the VIN biphasic configuration.
Time frame: 4 hours
Essential tremor's effect on gait will be assessed by the GAITRite system. Patients will walk along a GAITRite floor mat to have the various gait parameters such as step time measured. The GAITRite system translates movement metrics into an objective kinematic score. In this study, the reported kinematic scores represent motor function captured after 4 hours of active DBS - under either the participants' home settings or the VIN biphasic configuration.
Time frame: 4 hours
Essential tremor's effect on gait will be assessed by the GAITRite system. Patients will walk along a GAITRite floor mat to have the various gait parameters such as gait cycle time measured. The GAITRite system translates movement metrics into an objective kinematic score. In this study, the reported kinematic scores represent motor function captured after 4 hours of active DBS - under either the participants' home settings or the VIN biphasic configuration.
University of Florida
Other
Physiology, Imaging and Modeling of Deep Brain Stimulation for Essential Tremor
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03027310
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06403280
Basal Ganglia Diseases, Brain Diseases
Graz, Styria, Austria
View Trial DetailsNCT03884231
Basal Ganglia Diseases, Brain Diseases
Tucson, Arizona, United States
View Trial DetailsNCT05106816
Basal Ganglia Diseases, Brain Diseases
Gainesville, Florida, United States
View Trial Details